LabCorp's $85M Orchid Deal Depends On Divestment: FTC

Law360, New York (December 8, 2011, 5:04 PM EST) -- The Federal Trade Commission has asked Laboratory Corp. of America Holdings to divest a part of Orchid Cellmark Inc.’s paternity testing business in order to have its $85 million purchase of the rival DNA testing company approved, the agency said Thursday.

The FTC said it imposed the condition as part of a proposed agreement with the companies to resolve its complaint claiming that North Carolina-based LabCorp's April-announced acquisition of Orchid would have an anti-competitive effect on the paternity testing services market that government agencies rely on....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.